A Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of Circadin to Alleviate Sleep Disturbances in Children With Neurodevelopmental Disabilities

Trial Profile

A Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of Circadin to Alleviate Sleep Disturbances in Children With Neurodevelopmental Disabilities

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Oct 2017

At a glance

  • Drugs Melatonin (Primary)
  • Indications Developmental disabilities; Sleep disorders
  • Focus Registrational; Therapeutic Use
  • Sponsors NEURIM Pharmaceuticals
  • Most Recent Events

    • 10 Oct 2017 According to a a NEURIM Pharmaceuticals media release, patients are now being followed up to 78 weeks to assess the long-term efficacy and safety of PedPRM and results will be presented during 2018.
    • 10 Oct 2017 According to a a NEURIM Pharmaceuticals media release, study results will be presented at the American Academy of Child & Adolescent Psychiatry (AACAP) 64th Annual Meeting, (Washington DC, from October 23-28, 2017), and are in press in the Journal of American Academy of Child & Adolescent Psychiatry.
    • 10 Oct 2017 According to a a NEURIM Pharmaceuticals media release, main study results were presented during the World Sleep Congress (Prague, October 9-12) 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top